Fig. 8.

Systemic administration of the NPs. (a) Time-lapse illumination of subcutaneous tumors with I-R-Ap-AcDEX2 NPs. C57BL/6 mice bearing subcutaneous tumors were intravenously injected with I-R-Ap-AcDEX2 NPs (1 mg, with 30 μg of ICG in the NPs) or ICG (30 μg) via tail vein and then imaged for in vivo NIR fluorescence emission at the indicated time points. Circles indicate the location of tumors. (b–c) EL4 tumor challenge via systemic administration of the NPs. C57BL/6 female mice were inoculated with EL4 cells (1 × 10⁵) on day 0 by subcutaneous injection, subcutaneously immunized on day 1 under the scruff with PBS or the NPs, intravenously given a total of three injections with PBS or the NPs on days 7, 10 and 13. For laser-irradiated groups, the mice were irradiated with the 808 nm laser (1.0 W cm⁻², 3 min) 2 h after injection of the NPs or PBS on days 7, 10 and 13, respectively. Five more intravenous injections of I-R-Ap-AcDEX2 NPs and laser irradiations were given in the group (I-R-Ap-AcDEX2 NPs + Laser). (n = 5 mice for each group). ns: no significant difference, *p < 0.05, ***p < 0.001. The p values are analyzed by two-way ANOVA (Bonferroni post-test) with GraphPad Prism. (d) The survival curve of EL4 tumor challenge by systemic administration.